PHARMACOTHERAPY IN THE TREATMENT OF OBESITY

  • Floriana Elvira Ionică
  • Simona Negreș
  • Oana Cristina Șeremet
  • Cornel Chiriță
Keywords: anti-obesity pharmacotherapy, diethylpropion, lorcaserin, orlistat, phentermine/topiramate

Abstract

Background and Aims: In the last three decades, obesity and its related co morbidities has quickly increased. Sometime, obesity was viewed as a serious health issue in developed countries alone, but now is recognized as a worldwide epidemic, and its associated costs are enormous. Obesity is related with various diseases, like hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, chronic cardiovascular diseases, respiratory conditions, alongside chronic liver diseases, including non- alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This review purpose is to provide data on the current anti-obesity drugs, also available and in the development. Material and Methods: We searched MEDLINE from 2006 to the present to collect information on the anti-obesity pharmacotherapy. Results and Conclusions: In the patients with obesity related comorbidities, there may be an adaptation of the anti-obesity pharmacotherapy to the patients’ needs, in respect to the improvements of the cardiometabolic parameters. Although their efficacy was proven, the anti-obesity pharmacotherapies have presented adverse events that require a careful monitoring during treatment. The main obstacle for approve new drugs seems to be the ratio between the risks and the benefits, because of a long-time background of perilous anti-obesity drugs.

Published
2016-12-15
How to Cite
Ionică, Floriana, Simona Negreș, Oana Șeremet, and Cornel Chiriță. 2016. “PHARMACOTHERAPY IN THE TREATMENT OF OBESITY”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 23 (4), 415-22. https://rjdnmd.org/index.php/RJDNMD/article/view/75.
Section
Review Articles